Nano-sized drug particles to expand HIV treatment further

April 9, 2014
Nano-sized drug particles to expand HIV treatment further
Dr Paul L. Domanico: “This project partners two substantial organisations committed to transforming the treatment of disease for patients in low resource settings”

Research at the University of Liverpool could benefit millions of HIV patients in developing countries through a nano-technology programme aimed at making drug treatment more effective.

The Liverpool programme to date has focused on developing nano-sized particles of antiretroviral drugs to increase their stability and absorption. However, a significant number of HIV treatments are not compatible with current technologies.

Broaden the capabilities

To address this, the University is collaborating with the Clinton Health Access Initiative (CHAI) in an attempt to broaden the capabilities of nano-technology. They will work with a widely used HIV , and combine that with commonly used ingredients in an attempt to create stable nano-particles.

According to World Health Organisation (WHO) figures, 9.7 million people had access to antiretroviral therapy around the world in 2012, but there are estimated to be 35.3 million people living with HIV. With a limited health budget in developing countries, authorities face difficult challenges in making more treatment available.

Nanomedicine is an emerging field of drug development that utilises particles at the nano scale (one millionth of a millimetre). One of the benefits of these types of therapies is that they can increase the amount of drug where it is needed. In the case of this research, the goal is to prevent drug degradation in the intestine through the use of nano-particles.

This would result in more drug getting into the body to fight HIV. Since more of the drug is going where it is needed, the dosage can be reduced while maintaining therapeutic activity. The fundamental value is that with a similar health budget many more patients would receive quality care.

Liverpool pharmacologist, Professor Andrew Owen and CHAI senior director of research and development, Dr Paul L. Domanico are leading this project. Professor Owen said: "This project is about using practical science and clinical expertise to broaden the utility of a new technology. These approaches could deliver a step-change for drug delivery in cases of HIV."

Dr Domanico added, "This project partners two substantial organisations committed to transforming the treatment of disease for patients in low resource settings."

Nanomedicine candidates will be generated and characterised in the University's Department of Chemistry by Professor Steve Rannard's team and subsequently studied in the Department of Molecular and Clinical Pharmacology under the supervision of Professor Andrew Owen and Dr Marco Siccardi. The research will also use state-of-the-art mathematical modelling techniques to bridge between disciplines.

Preclinical data published

The research builds on existing HIV work between the University's Department of Molecular and Clinical Pharmacology and Department of Chemistry that has already received more than £6 million investment. The project will also be support by existing and on-going preclinical pharmacology studies performed by CHAI.

The Liverpool team has published preclinical data showing that that there may be benefits for dose reduction of other HIV drugs and clinical trials are planned for later in 2014. If successful these would form the first oral nanomedicines for HIV.

Explore further: HIV treatment while incarcerated helped prisoners achieve viral suppression

Related Stories

HIV treatment while incarcerated helped prisoners achieve viral suppression

March 31, 2014
Treating inmates for the human immunodeficiency virus (HIV) while they were incarcerated in Connecticut helped a majority of them achieve viral suppression by the time they were released.

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

April 7, 2014
The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults ...

Scientists to study the role genes play in treating tuberculosis

October 25, 2012
The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.

AIDS: Crimean drug users at risk, says NGO

March 20, 2014
More than 14,000 injecting drug users in Crimea risk being cut off from life-saving treatment and services prohibited in Russia, an NGO working to halt HIV spread warned on Thursday.

DNDi and Cipla advance development of pediatric 4-in-1 ARVs to fulfill new WHO guidelines

June 30, 2013
The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, ...

Nail fungus drug might help against HIV, study suggests

September 24, 2013
(HealthDay)—A common drug used to treat nail fungus may hold promise against HIV, the virus that causes AIDS, according to a new study.

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.